WT1 Immunity Via DNA Fusion Gene Vaccination in Haematological Malignancies by Intramuscular Injection Followed by Intramuscular Electroporation

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

February 1, 2011

Primary Completion Date

February 28, 2013

Study Completion Date

February 26, 2013

Conditions
Leukaemia (Acute)Leukaemia (Chronic)Leukaemia (Acute Myeloid)Leukaemia (Acute Lymphoblastic)Leukaemia (Acute Promyelocytic)
Interventions
BIOLOGICAL

p.DOM-WT1-37 DNA Vaccine and p.DOM-WT1-126 DNA Vaccine

p.DOM-WT1-37: 1mg/dose/vaccine p.DOM-WT1-126: 1mg/dose/vaccine The DNA vaccine will be administered 6 times at 4 weekly intervals. Responders (Immunological but without molecular progression) may continue vaccination 3 monthly to maximum of 24 months. The vaccines will be injected intramuscularly (im) followed by electroporation (EP) into separate locations.

Trial Locations (3)

EX2 5DW

Royal Devon and Exeter NHS Foundation Trust, Exeter

W12 0HS

Imperial College NHS Trust, London

SO16 6YD

Southampton University Hospitals NHS Trust, Southampton

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Imperial College Healthcare NHS Trust

OTHER

collaborator

Royal Devon and Exeter NHS Foundation Trust

OTHER

collaborator

Inovio Pharmaceuticals

INDUSTRY

collaborator

Efficacy and Mechanism Evaluation (EME) Programme

OTHER

collaborator

Leukemia Research Fund

OTHER

lead

University Hospital Southampton NHS Foundation Trust

OTHER

NCT01334060 - WT1 Immunity Via DNA Fusion Gene Vaccination in Haematological Malignancies by Intramuscular Injection Followed by Intramuscular Electroporation | Biotech Hunter | Biotech Hunter